MX2020011453A - Combinaciones para tratar el cancer. - Google Patents
Combinaciones para tratar el cancer.Info
- Publication number
- MX2020011453A MX2020011453A MX2020011453A MX2020011453A MX2020011453A MX 2020011453 A MX2020011453 A MX 2020011453A MX 2020011453 A MX2020011453 A MX 2020011453A MX 2020011453 A MX2020011453 A MX 2020011453A MX 2020011453 A MX2020011453 A MX 2020011453A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- treating cancer
- combinations
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Se desvelan métodos de tratamiento del cáncer que comprenden administrar ácido 17-cloro-5,13,14,22-tetrametil-28-oxa-2,9-ditia- 5,6,12,13,22-pentaazaheptaciclo[27.7.1.14,7.011,15.016,21.020,24. 030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35- tridecaeno-23-carboxílico, una sal farmacéuticamente aceptable del mismo; y acalabrutinib, o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862664356P | 2018-04-30 | 2018-04-30 | |
PCT/IB2019/053491 WO2019211721A1 (en) | 2018-04-30 | 2019-04-29 | Combinations for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020011453A true MX2020011453A (es) | 2020-12-07 |
Family
ID=66794041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020011453A MX2020011453A (es) | 2018-04-30 | 2019-04-29 | Combinaciones para tratar el cancer. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210030718A1 (es) |
EP (1) | EP3787620A1 (es) |
JP (1) | JP2021522246A (es) |
KR (1) | KR20210005182A (es) |
CN (1) | CN112040944A (es) |
AU (1) | AU2019263026B2 (es) |
BR (1) | BR112020022020A2 (es) |
CA (1) | CA3097486A1 (es) |
EA (1) | EA202092540A1 (es) |
MA (1) | MA52499A (es) |
MX (1) | MX2020011453A (es) |
SG (1) | SG11202010528XA (es) |
TW (1) | TW202014184A (es) |
WO (1) | WO2019211721A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020381240C1 (en) * | 2019-11-04 | 2024-02-15 | Astrazeneca Ab | Therapeutic combinations of acalabrutinib and capivasertib to treat B-cell malignancies |
IL293939A (en) * | 2019-12-18 | 2022-08-01 | Zeno Man Inc | macrocyclic compounds |
AU2022291381A1 (en) | 2021-06-11 | 2023-11-30 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
EP4351657A1 (en) | 2021-06-11 | 2024-04-17 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106243113B (zh) | 2011-07-19 | 2018-12-18 | 默沙东有限责任公司 | 作为btk抑制剂的选择的咪唑并吡嗪类 |
CN106714909A (zh) * | 2014-08-08 | 2017-05-24 | 药品循环有限责任公司 | 布鲁顿氏酪氨酸激酶抑制剂组合及其用途 |
CA3020378A1 (en) * | 2016-04-22 | 2017-10-26 | Astrazeneca Ab | Macrocyclic mcl1 inhibitors for treating cancer |
CN107056786B (zh) * | 2016-10-14 | 2019-05-07 | 苏州明锐医药科技有限公司 | 阿卡替尼的制备方法 |
-
2019
- 2019-03-05 TW TW108107170A patent/TW202014184A/zh unknown
- 2019-04-29 CA CA3097486A patent/CA3097486A1/en active Pending
- 2019-04-29 JP JP2020559437A patent/JP2021522246A/ja not_active Withdrawn
- 2019-04-29 AU AU2019263026A patent/AU2019263026B2/en not_active Ceased
- 2019-04-29 SG SG11202010528XA patent/SG11202010528XA/en unknown
- 2019-04-29 CN CN201980028857.5A patent/CN112040944A/zh active Pending
- 2019-04-29 EP EP19729355.8A patent/EP3787620A1/en not_active Withdrawn
- 2019-04-29 KR KR1020207034122A patent/KR20210005182A/ko unknown
- 2019-04-29 MA MA052499A patent/MA52499A/fr unknown
- 2019-04-29 WO PCT/IB2019/053491 patent/WO2019211721A1/en unknown
- 2019-04-29 EA EA202092540A patent/EA202092540A1/ru unknown
- 2019-04-29 US US17/047,931 patent/US20210030718A1/en not_active Abandoned
- 2019-04-29 MX MX2020011453A patent/MX2020011453A/es unknown
- 2019-04-29 BR BR112020022020-5A patent/BR112020022020A2/pt unknown
Also Published As
Publication number | Publication date |
---|---|
CN112040944A (zh) | 2020-12-04 |
WO2019211721A1 (en) | 2019-11-07 |
AU2019263026A1 (en) | 2020-12-17 |
EA202092540A1 (ru) | 2021-03-17 |
KR20210005182A (ko) | 2021-01-13 |
BR112020022020A2 (pt) | 2021-02-02 |
CA3097486A1 (en) | 2019-11-07 |
TW202014184A (zh) | 2020-04-16 |
SG11202010528XA (en) | 2020-11-27 |
JP2021522246A (ja) | 2021-08-30 |
AU2019263026B2 (en) | 2022-06-30 |
MA52499A (fr) | 2021-04-14 |
US20210030718A1 (en) | 2021-02-04 |
EP3787620A1 (en) | 2021-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020011453A (es) | Combinaciones para tratar el cancer. | |
MX2019013954A (es) | Inhibidores covalentes de kras. | |
MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
MX2018000777A (es) | Compuestos de quinazolina sustituido y su uso como inhibidores de proteinas kras, hras y/o nras mutantes g12c. | |
PH12016501394A1 (en) | Compounds for treating patients with ros1 mutant cancer cells | |
MX2021005075A (es) | Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion. | |
PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
MX2020013557A (es) | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo. | |
MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
MX2020010369A (es) | Particulas implantables y metodos relacionados. | |
CR20220215A (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
MX2021009439A (es) | Derivados de imidazo [2,1-f] [1,2,4] triazin-4-amina como agonista de tlr7. | |
CR20220216A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
MX2018015172A (es) | Metodos para tratar cancer pancreatico. | |
MX2020010618A (es) | Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a. | |
MX2021007247A (es) | Derivados de rapamicina. | |
PH12020552274A1 (en) | Formulations of an axl/mer inhibitor | |
MX2021012105A (es) | Compuestos de pirrol. | |
MX2022003585A (es) | Metodos para tratar hiperfenilalaninemia. | |
MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
ZA202206308B (en) | Ezetimibe and curcumin for use in cancer treatment | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
MX2021011529A (es) | Chiauranib para el tratamiento de cáncer de pulmón microcítico. | |
EP3781148A4 (en) | THERAPEUTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER WITH 6,8-BIS-BENZYLTHIO-OCTONIC ACID |